2024
Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn total
2022
Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2019
A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis
Della Seta M, Collettini F, Chapiro J, Angelidis A, Engeling F, Hamm B, Kaul D. A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis. Acta Radiologica 2019, 60: 1496-1503. PMID: 30841703, DOI: 10.1177/0284185119831692.Peer-Reviewed Original ResearchConceptsIntracranial progression-free survivalSingular brain metastasisStereotactic radiation therapyPre-treatment magnetic resonance imagingMagnetic resonance imagingBrain metastasesPrognostic factorsTumor volumeRadiation therapyCranial magnetic resonance imagingContrast-enhanced MRI scansMultivariable Cox regressionProgression-free survivalIntracranial malignant tumorPrediction of survivalOverall survivalMultivariable analysisPrognostic indexCox regressionRetrospective studyMalignant tumorsQuantitative imaging biomarkersMRI scansPatientsRadiomic biomarkersQuantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization
Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. Journal Of Nuclear Medicine 2019, 60: 1066-1072. PMID: 30655331, PMCID: PMC6681698, DOI: 10.2967/jnumed.118.219691.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBiomarkersCarcinoma, HepatocellularEmbolization, TherapeuticFeasibility StudiesFemaleHumansImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMicrospheresMiddle AgedMultimodal ImagingPrognosisRegression AnalysisRetrospective StudiesTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNon-HCC patientsTransarterial radioembolizationHepatocellular carcinomaBaseline imagingTumor responseTumor volumeChild-Pugh class B patientsBaseline imaging featuresClass B patientsNormal liver ratiosTotal tumor volumeSPECT/CTContrast-enhanced MRIQuantitative European AssociationMultiphasic contrast-enhanced MRIInstitutional review boardHigh TNRPreprocedural MRIChild-PughB patientsLiver criteriaTumor burdenClinical parametersHepatic malignanciesRetrospective study
2016
Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology 2016, 283: 160838. PMID: 27831830, PMCID: PMC5425309, DOI: 10.1148/radiol.2016160838.Peer-Reviewed Original ResearchConceptsNeuroendocrine liver metastasesWorld Health OrganizationContrast material-enhanced magnetic resonance (MR) imagesFirst TACE procedureResponse Evaluation CriteriaKaplan-Meier curvesTreatment response biomarkersTransarterial chemoembolization proceduresInstitutional review boardFirst TACELiver methodLiver metastasesIndependent predictorsTumor burdenRetrospective studyTACE proceduresCox regressionOnly biomarkerSurvival differencesChemoembolization proceduresTreatment responseResponse biomarkersPatientsSolid tumorsNormal liverImproved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT
Schernthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT. CardioVascular And Interventional Radiology 2016, 39: 1429-1437. PMID: 27380872, PMCID: PMC5009166, DOI: 10.1007/s00270-016-1406-2.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyDigital subtraction angiographyLiver metastasesDP-CBCTCone-beam CTDual-phase cone-beam CTContrast-enhanced magnetic resonance imagingSarcoma liver metastasesTumor-feeding arteriesMagnetic resonance imagingContrast agent injectionMetastatic diseaseMethodsThis IRBRetrospective studyCRCLMClinical impactArterial phaseCE-MRIDepiction rateResonance imagingAgent injectionSubtraction angiographyMetastasisTherapyHigh rate
2014
Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization
Schernthaner RE, Lin M, Duran R, Chapiro J, Wang Z, Geschwind JF. Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization. CardioVascular And Interventional Radiology 2014, 38: 929-936. PMID: 25476872, PMCID: PMC4457721, DOI: 10.1007/s00270-014-1026-7.Peer-Reviewed Original ResearchMeSH KeywordsAngiography, Digital SubtractionBile Duct NeoplasmsChemoembolization, TherapeuticCholangiocarcinomaCohort StudiesCone-Beam Computed TomographyFemaleHumansLiverMagnetic Resonance ImagingMaleMiddle AgedObserver VariationRadiography, InterventionalReproducibility of ResultsRetrospective StudiesConceptsDual-phase cone-beam CTConventional transarterial chemoembolizationDigital subtraction angiographyIntrahepatic cholangiocarcinomaICC lesionsTransarterial chemoembolizationCE-MRICone-beam CTContrast-enhanced magnetic resonance imagingMethodsThis retrospective studyProsthetic mitral valveMagnetic resonance imagingHigher detectability rateConsecutive patientsRetrospective studyMitral valveMore lesionsLesionsResonance imagingSubtraction angiographyRoutine useLesion visibilityTreatment planningChemoembolizationCholangiocarcinomaRadiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis
Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology 2014, 273: 746-758. PMID: 25028783, PMCID: PMC4263418, DOI: 10.1148/radiol.14140033.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDiffusion Magnetic Resonance ImagingFemaleGadolinium DTPAHumansImage Interpretation, Computer-AssistedImaging, Three-DimensionalLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSoftwareTreatment OutcomeConceptsPathologic tumor necrosisHepatocellular carcinoma lesionsTumor necrosisTransarterial chemoembolizationCarcinoma lesionsRadiologic–pathologic correlation studyTumor tissueMagnetic Resonance Imaging AssessmentDiagnostic accuracyInstitutional review board-approved retrospective studyOrthotopic liver transplantationTotal tumor volumeDiffusion-weighted MR imagingApparent diffusion coefficient (ADC) mapsNecrotic tumor tissueArterial phase MR imagesDiffusion coefficient mapsLast MR examinationLiver transplantationSurgical resectionLiver criteriaPathologic examinationRetrospective studyPhase MR imagesHistopathologic examination